Tempest Appoints John W. Frederick to Board of Directors, Strengthening Financial and Capital Markets Expertise
Key Highlights
- ➤Tempest (TPST) appoints John W. Frederick to its board of directors
- ➤Frederick most recently served as Skillsoft’s Chief Financial Officer
- ➤Frederick brings more than three decades of finance and capital-markets experience
- ➤Tempest’s lead candidate TPST-4003 targets CD19/BCMA and CD7 pathways
Expert Statements
Matt Angel, President and Chief Executive Officer of Tempest Therapeutics
“We are delighted to welcome John to our board as we enter an important phase in Tempest's evolution”
Matt Angel, President and Chief Executive Officer of Tempest Therapeutics
“His extensive experience leading public companies, optimizing capital structures and navigating complex financial environments will bring valuable perspective to our board.”
Matt Angel, President and Chief Executive Officer of Tempest Therapeutics
“We believe his financial acumen and strategic leadership will be particularly valuable as we prioritize disciplined capital deployment, achieve key development milestones with our in vivo CAR-T programs and position the company for long-term success.”
John W. Frederick, Director of Tempest Therapeutics
“I am excited to join Tempest's board of directors at such a pivotal time in its development.”
John W. Frederick, Director of Tempest Therapeutics
“The Company's innovative approach to in vivo CAR-T therapy represents a compelling opportunity to transform treatment for patients with significant unmet needs across multiple disease types.”
John W. Frederick, Director of Tempest Therapeutics
“I look forward to working alongside the board and leadership team to support the company's strategic priorities, advance its promising pipeline and help build a strong foundation for sustainable, long-term growth and shareholder value.”
BRISBANE, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage biotechnology company developing in vivo CAR-T therapies designed to reset dysfunctional immunity in cancer and autoimmune disease, today announced that John W. Frederick has been appointed to its board of directors. Mr. Frederick brings extensive executive leadership experience spanning financial strategy, capital markets, corporate governance and operational transformation across public and private companies.
“We are delighted to welcome John to our board as we enter an important phase in Tempest's evolution,” said Matt Angel, Ph.D., President and Chief Executive Officer of Tempest. “His extensive experience leading public companies, optimizing capital structures and navigating complex financial environments will bring valuable perspective to our board. We believe his financial acumen and strategic leadership will be particularly valuable as we prioritize disciplined capital deployment, achieve key development milestones with our in vivo CAR-T programs and position the company for long-term success.”
Get started
Create a free account to read the full story.